Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis

Carcinogenesis

Volumn 36, Issue 3, 2014, Pages 390-399

  Zhang, Lin ^a,b   Xia, Limin ^a   Zhao, Lina ^a   Chen, Zhangqian ^a   Shang, Xin ^a   Xin, Jing ^c   Liu, Muhan ^c   Guo, Xuegang ^a   Wu, Kaichun ^a   Pan, Yanglin ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Culture Work General Stand of the People's Liberation Army General Political Department   (China)

^c XIDIAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 206; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG; MET PROTEIN, HUMAN; MIRN206 MICRORNA, HUMAN; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; GASTRECTOMY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; ANIMAL; BAGG ALBINO MOUSE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; PAIRED BOX TRANSCRIPTION FACTORS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84924433529     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv009     Document Type: Article

References (49)

1. Jemal, A. et al. (2010) Cancer statistics, 2010. CA. Cancer J. Clin., 60, 277-300.
2. Ferlay, J. et al. (2010) Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int. J. Cancer, 127, 2893-2917.
3. Lai, E.C. (2002) Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet., 30, 363-364.
4. Ambros, V. (2001) microRNAs: tiny regulators with great potential. Cell, 107, 823-826.
5. Hiyoshi, Y. et al. (2009) MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin. Cancer Res., 15, 1915-1922.
6. Segura, M.F. et al. (2009) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl Acad. Sci. USA, 106, 1814-1819.
7. Valastyan, S. et al. (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell, 137, 1032-1046.
8. Tavazoie, S.F. et al. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147-152.
9. Hurst, D.R. et al. (2009) Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res., 69, 7495-7498.
10. Zhang, L. et al. (2013) miR-206 inhibits gastric cancer proliferation in part by repressing cyclin D2. Cancer Lett., 332, 94-101.
11. Yan, D. et al. (2009) MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J. Biol. Chem., 284, 29596-29604.
12. Song, G. et al. (2009) MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J. Biol. Chem., 284, 31921-31927.
13. Vickers, M.M. et al. (2012) Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin. Exp. Metastasis, 29, 123-132.
14. Adams, B.D. et al. (2009) The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol. Endocrinol., 23, 1215-1230.
15. Wang, X. et al. (2011) MicroRNA-206 is associated with invasion and metastasis of lung cancer. Anat. Rec. (Hoboken)., 294, 88-92.
16. Negrini, M. et al. (2008) Breast cancer metastasis: a microRNA story. Breast Cancer Res., 10, 203.
17. Tie, J. et al. (2010) MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet., 6, e1000879.
18. Pan, Y. et al. (2006) Cellular prion protein promotes invasion and metastasis of gastric cancer. FASEB J., 20, 1886-1888.
19. Epstein, J.A. et al. (1996) Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc. Natl Acad. Sci. USA, 93, 4213-4218.
20. Mascarenhas, J.B. et al. (2010) PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res., 23, 225-237.
21. Anderson, C. et al. (2006) MIR-206 regulates connexin 43 expression during skeletal muscle development. Nucleic Acids Res., 34, 5863-5871.
22. Rao, P.K. et al. (2006) Myogenic factors that regulate expression of muscle- specific microRNAs. Proc. Natl Acad. Sci. USA, 103, 8721-8726.
23. Chi, N. et al. (2002) Getting your Pax straight: Pax proteins in development and disease. Trends Genet., 18, 41-47.
24. Muratovska, A. et al. (2003) Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene, 22, 7989-7997.
25. Lang, D. et al. (2007) PAX genes: roles in development, pathophysiology, and cancer. Biochem. Pharmacol., 73, 1-14.
26. Robson, E.J. et al. (2006) A PANorama of PAX genes in cancer and development. Nat. Rev. Cancer, 6, 52-62.
27. Wang, Q. et al. (2008) Pax genes in embryogenesis and oncogenesis. J. Cell. Mol. Med., 12, 2281-2294.
28. Margue, C.M. et al. (2000) Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene, 19, 2921-2929.
29. Chen, J. et al. (2012) Clinical significance and prognostic value of PAX3 expression in human glioma. J. Mol. Neurosci., 47, 52-58.
30. Kubic, J.D. et al. (2012) GSK-3 promotes cell survival, growth, and PAX3 levels in human melanoma cells. Mol. Cancer Res., 10, 1065-1076.
31. Scholl, F.A. et al. (2001) PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res., 61, 823-826.
32. Fang, W.H. et al. (2014) PAX3 in neuroblastoma: oncogenic potential, chemosensitivity and signalling pathways. J. Cell. Mol. Med, 18:38-48.
33. Harris, R.G. et al. (2002) The expression of the developmentally regulated proto-oncogene Pax-3 is modulated by N-Myc. J. Biol. Chem., 277, 34815-34825.
34. Li, X. et al. (2012) Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene, 31, 3419-3430.
35. Salem, C.E. et al. (2000) PAX6 methylation and ectopic expression in human tumor cells. Int. J. Cancer, 87, 179-185.
36. Bottaro, D.P. et al. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science, 251, 802-804.
37. Trusolino, L. et al. (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol., 11, 834-848.
38. Gherardi, E. et al. (2012) Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer, 12, 89-103.
39. Danilkovitch-Miagkova, A. et al. (2002) Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest., 109, 863-867.
40. Migliore, C. et al. (2008) Molecular cancer therapy: can our expectation be MET? Eur. J. Cancer, 44, 641-651.
41. Desiderio, M.A. (2007) Hepatocyte growth factor in invasive growth of carcinomas. Cell. Mol. Life Sci., 64, 1341-1354.
42. Di Renzo, M.F. et al. (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 19, 1547-1555.
43. You, H. et al. (2011) c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology, 54, 879-889.
44. Ma, P.C. et al. (2003) c-MET mutational analysis in small cell lung cancer:novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res., 63, 6272-6281.
45. Janjigian, Y.Y. et al. (2011) MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol. Biomarkers Prev., 20, 1021-1027.
46. Graziano, F. et al. (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J. Clin. Oncol., 29, 4789-4795.
47. Benvenuti, S. et al. (2007) The MET receptor tyrosine kinase in invasion and metastasis. J. Cell. Physiol., 213, 316-325.
48. Birchmeier, C. et al. (2003) Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 4, 915-925.
49. Liu, X. et al. (2013) Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma. Oncol. Rep., 29, 1415-1420.